Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.4630 -0.0030 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
21 22 Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023
Via Benzinga
AT&T, Carvana, Northern Trust, And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 250 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
The Latest Analyst Ratings for bluebird bio
Via Benzinga
Why Is Bluebird Bio (BLUE) Stock Up 17% Today?
Bluebird Bio received a major lift from JPMorgan Chase regarding its gene-editing therapeutic, sending BLUE stock flying. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why bluebird bio Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Gainers 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) shares surged 23.6% to $2.99 in pre-market trading after dipping 21% on Tuesday. 
Via Benzinga
Cisco To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Wednesday
Wedbush boosted the price target for Domino's Pizza, Inc. (NYSE: DPZ) from $365 to $430. Wedbush analyst Nick Setyan maintained an Outperform rating. Domino's shares rose 0.7% to close at $392.29 on... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday! 
Via InvestorPlace
Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street
This company could soon commercialize its third gene therapy. 
Via The Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
Is Bluebird Bio Stock a Buy Now?
If the company can pull off a comeback, investors who get in now will see incredible returns. But how likely is a comeback? 
Via The Motley Fool
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
Caterpillar To Rally Over 37%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc boosted the price target for Pure Storage, Inc. (NYSE: PSTG) from $35 to $40. Keybanc analyst Thomas Blakey maintained the stock with an Overweight rating. Pure Storage shares fell 2.1% to... 
Via Benzinga
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
This market-beating biotech stock still has more room to run. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% on Thursday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
Via Benzinga
Intel, Saia, Charter Communications And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
From bluebird bio
Via Business Wire
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.